

REMARKS

Claims 1-8 are pending in this application. Claims 9-13, 21 and 22 have been cancelled as drawn to non-elected inventions. Claims 3 and 4 have been amended to correct grammatical errors. No new matter is introduced thereby.

Restriction/Species Election

The claims of the instant application have been restricted, under 35 U.S.C. §§ 121 and 372, into three Groups, as follows:

Group I (claims 1-8) drawn to compounds represented by Formula I.

Group II (claims 9-12) drawn to methods of using the compound in Group I.

Group III (claims 13, 21 and 22) drawn to methods of making the compound in Group I.

Applicants hereby elect the claims of Group I for prosecution at this time, without traverse, reserving the right to pursue the prosecution of unelected subject matter at a later date.


Regarding the election of a specie within Group I, applicants elect the following values of substituents for Formula I (claim 1): R₁ is CH₃; R₂ is CN; R₄ is hydrogen; X is oxygen; X₁ is CH₃; X₂ is cyclopentyl; Y is oxygen; and Y₁ and Y₂ are hydrogen.

Conclusion

Applicants respectfully submit that the pending claims are allowable, and request a Notice of Allowance at this time. Authorization is hereby given to charge any fees deemed to be due in connection with this Response to Deposit Account No. 50-0912.

Respectfully submitted,

PALLE et al.

By: 
George E. Heibel, Ph.D.
Reg. No. 42,648

Dated: September 11, 2008

Correspondence Address:

Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Telephone: (609) 720-5334
Facsimile: (609) 514-9779